Appendix 1 – Results of all years MTC adjusted for baseline ARR

Table A.1.1 Annualised relapse rates RR (all years adjusted for baseline ARR)

	Teriflunomide 14mg	Placebo
	Rate Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	0.94 [0.72, 1.25]	[redacted]
IM IFNβ-1a 30 µg	0.78 [0.61, 1.01]	[redacted]
SC IFNβ-1a 44 µg	0.99 [0.77, 1.30]	[redacted]
GA 20 mg	0.99 [0.79, 1.24]	[redacted]
Fingolimod 0.5 mg	1.41 [1.14, 1.77]	[redacted]
Natalizumab 300 mg	2.10 [1.61, 2.76]	[redacted]

Table A.1.2 SAD 3 month HR (all years adjusted for baseline ARR)

	Teriflunomide 14mg	Placebo
	Hazard Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	0.59 [0.34, 1.03]	[redacted]
IM IFNβ-1a 30 µg	0.72 [0.46,1.16]	[redacted]
SC IFNβ-1a 22 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	0.82 [0.54,1.27]	[redacted]
GA 20 mg	0.76 [0.49, 1.20]	[redacted]
Fingolimod 0.5 mg	0.91 [0.63, 1.29]	[redacted]
Natalizumab 300 mg	1.14 [0.73,1.8]	[redacted]

Table A.1.3. Discontinuation rate ORs (all years MTC adjusted for baseline ARR)

	Teriflunomide 14mg	Placebo
	Odds Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	1.93 [1.19, 3.04]	[redacted]
IM IFNβ-1a 30 µg	1.18 [0.74, 1.84]	[redacted]
SC IFNβ-1a 22 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	0.88 [0.60,1.26]	[redacted]
GA 20 mg	1.47 [1.02, 2.05]	[redacted]
Fingolimod 0.5 mg	1.52 [1.01, 2.17]	[redacted]
Natalizumab 300 mg	1.34 [0.82, 2.22]	[redacted]

Appendix 2 – Results of the sensitivity analysis all years MTC adjusted for baseline ARR, assuming a 1:1 year 2:1 ratio where data doesn't exist for relapse rates 1 year prior, and the corresponding ICERs for the scenario of Data Request 1

This analysis is the same as base case all years adjusted for baseline ARR MTC but where data exists for 2 years prior relapse rates but not for one year a 1:1 year 2 to year 1 ratio is assumed to estimate 1 year ARR rather than assuming that the 2 year relapse rates are 1.49 times greater than the 1 year relapse rates as was done in the base case analysis (see page 3 of the methods report for rationale for base case assumption).

In Appendix 2 we present:

- The sensitivity analysis MTC results (Tables A.2.1 - A.2.3)
- ICERs based on output from this sensitivity analysis MTC (Table A.2.4.)

ICER analysis is based on the model run with the following assumptions

- The ERGs preferred scenario:
  - Natural history progression data from placebo arms of TOWER and TEMSO
  - Baseline characteristics and initial EDSS distribution from TOWER and TEMSO
  - ERG amended calculation for SPMS conversion probabilities
  - Non-health costs not included
  - Utilities observed in TEMSO, using increments from Orme for high EDSS states where trial data were not available
- Waning of treatment effect is 75% treatment effect after 2 years and 50% treatment effect after 5 years.

Table A.2.1 Sensitivity analysis: annualised relapse rates RR from all years adjusted for baseline ARR, assuming a 1:1 year 2:1 ratio where data doesn't exist for relapse rates 1 year prior (see Appendix 1 for base case)

	Teriflunomide 14mg	Placebo
	Rate Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]
Fingolimod 0.5 mg	[redacted]	[redacted]
Natalizumab 300 mg	[redacted]	[redacted]

Table A.2.2 Sensitivity analysis: SAD 3 month HR from all years adjusted for baseline ARR, assuming a 1:1 year 2:1 ratio where data doesn't exist for relapse rates 1 year prior (see Appendix 1 for base case)

	Teriflunomide 14mg	Placebo
	Hazard Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 22 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]
Fingolimod 0.5 mg	[redacted]	[redacted]
Natalizumab 300 mg	[redacted]	[redacted]

Table A.2.3. Sensitivity analysis: discontinuation rate ORs from all years adjusted for baseline ARR, assuming a 1:1 year 2:1 ratio where data doesn't exist for relapse rates 1 year prior (see Appendix 1 for base case)

	Teriflunomide 14mg	Placebo
	Odds Ratio [95% CrI]	
Teriflunomide 14mg		[redacted]
IFNβ-1b 250 µg	[redacted]	[redacted]
IM IFNβ-1a 30 µg	[redacted]	[redacted]
SC IFNβ-1a 22 µg	[redacted]	[redacted]
SC IFNβ-1a 44 µg	[redacted]	[redacted]
GA 20 mg	[redacted]	[redacted]
Fingolimod 0.5 mg	[redacted]	[redacted]
Natalizumab 300 mg	[redacted]	[redacted]

Table A.2.4 Probabilistic results of teriflunomide versus all comparators using sensitivity analysis all years MTC adjusted for baseline ARR, assuming a 1:1 year 2:1 ratio where data doesn't exist for relapse rates 1 year prior (results in Tables A.2.1 - A.2.4)

Technologies	Total costs (£)	Total QALYs	Inc costs (£)	Inc QALYs	ICER versus baseline (£)	ICER (£) teriflunomide versus comparator
Glatiramer acetate	[redacted]	[redacted]				£25,033
Teriflunomide	[redacted]	[redacted]	3,811	0.152	£25,033	
IFNβ-1a 44µg (Rebif)	[redacted]	[redacted]	7,462	-0.060	Dominated	Dominated
IFNβ-1b	[redacted]	[redacted]	15,309	-0.226	Dominated	Dominated
IFNβ-1a (Avonex)	[redacted]	[redacted]	16,077	-0.106	Dominated	Dominated
IFNβ-1a 22µg (Rebif)	[redacted]	[redacted]	30,283	0.312	£97,134	£165,928